Bristol-Myers Squibb (BMY) Tops Q3 EPS by 22c, Offers Guidance
Tweet
Share
E-mail
Get Alerts BMY Hot Sheet
Price: $64.69 -3.19%
EPS Growth %: +5.5%
Financial Fact:
Provision for income taxes: 344M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +5.5%
Financial Fact:
Provision for income taxes: 344M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Bristol-Myers Squibb (NYSE: BMY) reported Q3 EPS of $2.00, $0.22 better than the analyst estimate of $1.78. Revenue for the quarter came in at $11 billion versus the consensus estimate of $10.98 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2023 EPS of $7.50-$7.65, versus the consensus of $7.36.
For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- Braze, Inc. (BRZE) Tops Q2 EPS by 4c; offers guidance
- UBS upgrades Lockheed Martin to Buy, sees 26% upside on missile growth
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
